Disclaimer

You are now leaving lundbeck.com. Please note that the information contained in the site you are linking to may not be fully compliant with regulatory environment and that product related information should be checked against the corresponding consumer medicine information or by asking your doctor. Any information provided should be discussed with your health care professional and does not replace the advice and treatment of your doctor. We hope you will visit us again soon.

Go to

Cancel

Léčivé přípravky ve výzkumu

Léčivé látky ve výzkumu

Naši pracovníci ve výzkumu a vývoji se soustřeďují na mechanismy vzniku a rozvoje onemocnění mozku. Směřujeme společně k cíli přinést nové přístupy k léčbě, které stanoví novou definici standardní péče o pacienty a prozkoumávat oblasti, kde je největší nenaplněná potřeba léčby.
Projekt Oblast Fáze 1 Fáze 2 Fáze 3
Brexpiprazole Agitation in dementia of the Alzheimer’s type 3

Mechanizmus účinku

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Brexpiprazole Post-Traumatic Stress Disorder 3

Mechanizmus účinku

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Brexpiprazole Borderline Personality Disorder 2

Mechanizmus účinku

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Projekt Oblast Fáze 1 Fáze 2 Fáze 3 Filing
Eptinezumab (anti-CGRP mAb) Migraine prevention Filing

Mechanizmus účinku

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Eptinezumab (anti-CGRP mAb) Episodic cluster headache 3

Mechanizmus účinku

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Brexpiprazole* Agitation in Alzheimer's disease 3

Mechanizmus účinku

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* PTSD 3

Mechanizmus účinku

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* Borderline Personality DIsorder 2

Mechanizmus účinku

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. Serotonergic and Dopaminergic stabilization may directly address the pathways implicated in the BPD features of impulse aggression (SER), and emotional dysregulation, impulsivity, and cognitive disturbances (DA).

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Aripiprazole 2-month injectable* Schizophrenia + Bipolar I Disorder 1

Mechanizmus účinku

Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AG06466 (MAGL inhibitor)* PTSD, fibromyalgia, MS spasticity 1

Mechanizmus účinku

Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including PTSD, Fibromyalgia and spasticity in patients with multiple sclerosis.

*MAGL: Monoacylglycerol lipase. PTSD, fibromyalgia, and MS spasticity studies have been initiated, one additional Phase Ib study within psychiatry/neurology will be explored during 2021.

Lu AG06479 (MAGL inhibitor)* Neurology, Psychiatry 1

Mechanizmus účinku

Lu AG06479 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.

*MAGL: Monoacylglycerol lipase.

Lu AF82422 (alpha-synuclein mAb) Multiple system atrophy 1

Mechanizmus účinku

Lu AF82422 is a monoclonal antibody targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders.

Lu AF28996 (D1 D2 agonist) Parkinson's disease 1

Mechanizmus účinku

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

Lu AG09222 (PACAP mAb)* Migraine 1

Mechanizmus účinku

LU AG09222 is a monoclonal antibody designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) signaling for migraine prevention. PACAP has emerged as a signaling molecule in the pathophysiology of migraine.

*PACAP: Pituitary adenylate cyclase-activating polypeptide

Lu AF87908 (Tau mAb) Tauopathies 1

Mechanizmus účinku

Lu AF87908 (Tau mAb) is a monoclonal antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

Více z Lundbecku

Výzkum a vývoj

Výzkum a
vývoj nových a vylepšených léčiv je podstatou toho co děláme.

Toto je Lundbeck

Specializovaná
farmaceutická společnost zaměřená výhradně na mozková onemocnění.

Porozumění  mozkovým onemocněním

Cesta ke zdraví mozku začíná pochopením chorob v mozku.